• The Office of Technology Licensing & Industry Relations is pleased to welcome Ms Donna Tumminello to our staff as the Assistant Director for Business Development

2002/08/31

• Posted Notice of Form 2 Conflict of Interest Disclosure requirement for 2002 - 2003 and updated Form 2

2002/07/27

• Posted announcement of an OTTL seminar "Is There a Company in Your Future" - August 7

2002/07/18

• NIH has posted a Web page on Conflict of Interest

2002/05/14

• Conflict of interest Investigator Disclosure Policy (P-209) and Scholarly Misconduct Policy (P-210) have been added to the Campus Policy Manual

2002/04/23

• Chancellor King will honor 15 Inventors and Enterpreneurs who contributed to Stony Brook's leadership within SUNY in the development of significant intellectual property. They include: Barry S. Coller (currently, Rockefeller University), Lorne M. Golub (Oral Biology & Pathology), Arie E. Kaufman (Computer Science), Stanley Fields (currently, University of Washington), Iwao Ojima (Chemistry), Paul Adams (Neurobiology), Yi-Xian Qin (Biomedical Engineering), Benjamin J. Luft (Medicine), Gail Mandel and Simon Halegoua (Neurobiology & Behavior), Paul Fisher (Pharmacology), Erwin London (Biochemistry), Dafna Bar-Sagi (Microbiology), James Quigley (currently, Scripps Institute) and Edmund F. La Gamma (Pediatrics).

2002/01/17

2001/12/05

2001/07/16

SEMINAR ON PATENTS, LICENSING AND TECHNOLOGY TRANSFER, The first in an ongoing series of discussions about inventing in research.

The Office of Technology Licensing and Industry Relations is organizing a series of seminars on patents, licensing and technology transfer.

The objectives of this initiative are:

The first of these ongoing seminars was held on Tuesday, July 24, 11 am at Life Science Building, Room 038

The title of the seminar was:

"PATENT ISSUES: WHAT YOU NEED TO PROTECT YOUR DISCOVERIES"

The speakers were Paul Fehlner, Ph.D., J.D. and Tom Triolo, Ph.D.

One of the properties of new knowledge is its propensity for revealing new ways of doing practical things. In other words, like it or not, your scientific discovery may lead you to an "invention."

Then what?
Paul Fehlner is a partner at Darby & Darby, one of the world's premier patent law firms. Tom Triolo (link to http://darbylaw.com/tt.html) will accompany Dr. Fehlner. Dr. Triolo, who received his Ph.D. in Biochemistry at Stony Brook, is an Associate at Darby & Darby.

They have generously agreed to give us some sensible answers to "Then what?" for biotech-related inventions. In the age of genomics and proteomics (already morphing into "phenomics" and "biomics"), it's hard even to know what an "invention" is, much less whether or not it can be patented and whether or not the patent will be worth anything. Dr. Fehlner will present and explain several "points to consider" in evaluating biotech inventions at the dawning of the "Age of Biology."